Prescription Digital Therapeutics

Diana Brixner, PhD, FAMCP, examines the payer perspective on including Prescription Digital Therapeutics in formularies, utilizing real-world evidence as a key metric to assess the impact, cost-effectiveness, and patient benefit of these innovative digital treatments.

A medical professional examines the potential for cost-effective frontline treatments and personalized care delivered through a mobile application at the patient's own pace, emphasizing the significance of high self-motivation and patient activation, while also discussing the role of prescription digital therapeutics in adjunct therapy.

Mahsa Salsabili, PharmD, PhD, presents an overview of prescription digital therapeutics and their application in addressing unmet patient needs across various disease states, including diabetes, addiction, and mental health conditions.

Digital health platform Wellvolution adds Spanish webpage and an at-home hypertension tracking feature.

The corresponding author of a study published in Health Affairs of the research supporting 20 FDA-authorized prescription digital therapeutics (PDTs) sees some positives but also an overall lack of rigor and the need for at least one high-quality clinical trial for each PDT.

Prescription digital therapeutics (PDTs) have great potential for treating a wide range of conditions, so studying the quality of the evidence supporting their efficacy and safety is important, says the corresponding author of a study on PDTS published in this month's Health Affairs.

There were some positive findings. But of the 20 FDA-authorized prescription digital therapeutics (PDTs) identified by researchers, only two met all the criteria for high-quality research. The results were published in Health Affairs.

Otsuka American Pharmaceutical is tracking payer practices and attitudes about digital therapeutics with a series of four surveys.

Results of a randomized trial reported in The Lancet Digital Health suggest a role for internet-based cognitive behavioral therapy, but many of the study volunteers were left with symptoms that would classify them as having major depressive disorder.

Lisa Rometty, CEO at Zerigo Health, discusses the challenges and opportunities for growth within the digital health landscape, as well as how Zerigo plans to collaborate with patients and payers to make sure digital health tools are accessible and affordable.

When compared to a double reading of a mammogram screening by two radiologists, a double reading by one radiologist plus AI demonstrated a 4% higher non-inferior cancer detection rate, highlighting the potential of AI in enhancing cancer detection in mammography screening.

Mahana’s company’s irritable bowel syndrome digital therapy was the first to digital therapy to gain clearance from the FDA.

Akili executives said a focus on non-prescription digital therapies removes the barriers payers place on access and creates a more sustainable business.

The first-ever machine learning-based model was developed to provide preoperative predictions of weight trajectories up to 5 years after surgery, simultaneously for three of the most common types of bariatric surgery.

However, patients who cannot get insurance coverage will be able to access AspyreRx at a significant self-pay discount.

In two-thirds of published studies, digital therapeutics were found to be cost-effective, and they led to cost savings in most of the other studies. However, most of the research was funded by industry and that might limit its impact.

More than half of participants completed the eight-week course, the authors said.

Big Health CEO Arun Gupta says digital therapeutics companies must "rigorously engage” with payers and focus on broad adoption of their products.

Although they used the app, participants referred by the legal system typically used it to connect with social workers or other services.

The study found the pricing for the therapy made it unlikely to be more cost-effective than in-person physical therapy.

Many countries still do not have official frameworks with which to evaluate digital therapies.

Medical experts discuss the impact of health inequities on the optimization of prescription digital therapeutic usage.

Through the inclusion of prescription digital therapeutics in individualized treatment plans, payers and providers are able to provide optimal and cost-effective care.

The product specifically looks at the potential to address negative symptoms of schizophrenia through digital health tools.

The company says the video game-based therapy improved measures of attention and quality of life for adults with ADHD.

A new study shows a digital therapeutic for insomnia works, but with important caveats.

Megan Coder, PharmD, MBA, leads a discussion surrounding the evolution of software applications in the clinical setting.